Glaxo gets injunction against Novartis division over asthma drug, WSJ reports

News Breaks

March 21, 2014 13:16 EDT GSK, NVS Glaxo gets injunction against Novartis division over asthma drug, WSJ reports
GlaxoSmithKline (GSK) has obtained a preliminary injunction to prevent Novartis’ (NVS) generic-drug division Sandoz from selling its AirFluSal Forspiro inhaler, a rival to Glaxo’s Advair inhaler, in Germany due to its purple color, according to the Wall Street Journal. Glaxo is working to hold onto the sales of its $9B Advair treatment, which lost patent protection in most of Europe last year. Reference Link

News For GSK;NVS From The Last 14 Days

Check below for free stories on GSK;NVS the last two weeks.

March 20, 2014 09:10 EDT GSK On The Fly: Pre-market Movers
UP AFTER EARNINGS: Burlington Stores (BURL), up 5%… Lennar (LEN), up 2%… BG Medicine (BGMD), up 16%. ALSO HIGHER: Synta Pharmaceuticals (SNTA), up 20% after announcing positive interim results from ganetespib trial… First Solar (FSLR), up 3.5% after the company’s price target was raised at Deutsche Bank, JPMorgan and RW Baird following the company issued it FY15 outlook yesterday. DOWN AFTER EARNINGS: Guess (GES), down 5%… Tilly’s (TLYS), down 7%… ExOne (XONE), down 12%. Peers in 3D space down as well, with 3D Systems down 3% and Stratasys (SSYS) down 2%. ALSO LOWER: Agenus (AGEN), down 18% after announcing that GlaxoSmithKline’s (GSK) MAGRIT study, which contains Agenus’QS-21 Stimulon adjuvant, did not meet its first or second co-primary endpoint… Cinedigm Digital (CIDM), down 12% after filing to sell common stock. 08:34 EDT NVS Piper Jaffray’s biopharm analyst holds an analyst/industry conference call
Subscribe for More Information 05:51 EDT GSK GSK’s MAGRIT study did not meet first or second co-primary endpoint
Subscribe for More Information 05:38 EDT NVS Novartis to introduce Lucentis in pre-filled syringe
Subscribe for More Information March 19, 2014 13:32 EDT NVS Novartis reports secondary survival endpoint data in Afinitor trial
Subscribe for More Information 08:38 EDT NVS UBS holds a field trip
Subscribe for More Information 07:28 EDT NVS Sachs Associates to hold a forum
Subscribe for More Information March 18, 2014 14:03 EDT NVS Novartis lymphocytic leukemia treatment granted FDA orphan status
According to a post on the FDA’s website, Novartis’ autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 for the treatment of chronic lymphocytic leukemia has received orphan designation. Reference Link 12:21 EDT NVS Novartis in advanced talks to buy Israeli stem cell company, Globes says
Novartis is in “advanced talks” to buy Israeli stem cell treatments developer Gamida Cell for up to $600M ,according to Globes, which cited unnamed sources. Gamida Cell, however, has not totally abandoned a plan to launch an IPO on Wall Street, the website added. Reference Link 11:46 EDT NVS Court says Barr Labs did not infringe on Alcon patents, Reuters says
Subscribe for More Information March 17, 2014 10:46 EDT GSK Leerink’s biopharma analysts hold an analyst/industry conference call
Analysts, along with two MEDACorp key opinion leaders (KOL) discuss opportunities for respiratory biologics for the treatment of severe asthma, with an emphasis on antibodies to IL-5 (AZN/GSK/TEVA) IL-4 (SNY/REGN) and IL-13 (AZN/RHHBY) on an Analyst/Industry conference call to be held on March 17 at 11 am. March 14, 2014 08:18 EDT GSK Theravance, GSK announce positive results from combination therapy COPD study
GlaxoSmithKline (GSK) and Theravance (THRX) announced positive results from three phase III studies. Two studies comparing the efficacy and safety of the combination anticholinergic / long-acting beta2-adrenergic agonist, Anoro Ellipta with inhaled corticosteroid / long-acting beta2-adrenergic agonist combination, Advair Diskus and the third comparing the efficacy and safety of Anoro Ellipta with Seretide Diskus ‘FSC 500/50’ in patients with chronic obstructive pulmonary disease, or COPD, and no history of moderate to severe COPD exacerbations in the last year. In each of the studies UMEC/VI achieved a statistically significant improvement in lung function, measured as weighted mean forced expiratory volume in one second over 0-24 hours at the end of the 12 week study, compared to either dose of FSC. March 13, 2014 12:40 EDT NVS Novartis initiated with an Underweight at Morgan Stanley
Subscribe for More Information 08:14 EDT GSK GlaxoSmithKline, Theravance announce SUMMIT recruitment completed
Subscribe for More Information 05:40 EDT NVS Novartis meningitis B vaccine receives recommendation for infants in Australia
Subscribe for More Information March 12, 2014 14:31 EDT GSK Leerink’s biotech and pharma analysts hold an analyst/industry conference call
Subscribe for More Information 13:22 EDT GSK GlaxoSmithKline says phase III studies for mepolizumab meet primary endpoints
Subscribe for More Information March 10, 2014 10:04 EDT GSK GlaxoSmithKline increases stake in Indian Pharmaceuticals subsidiary to 75%
Subscribe for More Information 08:35 EDT NVS Anacor names Vince Ippolito as Chief Commercial Officer
Anacor Pharmaceuticals (ANAC) announced the appointment of Vince Ippolito as Executive Vice President and Chief Commercial Officer. Ippolito has over 25 years of experience leading specialty medical sales and marketing efforts at Valeant Pharmaceuticals (VRX), Medicis Pharmaceutical Corporation and Novartis AG (NVS). 07:41 EDT GSK Edison Electric Institute to hold a conference
International Utility Conference is being held in London, England on March 10-11.